It has been revealed that the presence of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer can aid in independently predicting the risk of recurrence of the disease in patients who had undergone surgery after neoadjuvant chemotherapy. This may represent an important novel stratification factor for future post-neoadjuvant trials.
Patients with triple-negative breast cancer with residual disease have an exceptionally high risk of recurrence and novel therapies and technologies are thus essential, including those that can potentially predict the risk of relapse. ctDNA or plasma-derived tumour DNA is being explored as a way to detect cancer, guide treatment, and monitor patients during remission as the presence of ctDNA can signal the presence of cancer.
Researchers analysed plasma samples collected from 196 patients enrolled in the BRE12-158 clinical trial, which studied genomically directed therapy versus physician’s choice of treatment after preoperative chemotherapy in patients with triple-negative breast cancer . In this study, ctDNA was sequenced in 142 patients and mutated ctDNA was detected in 63% of the patients. The most commonly mutated gene was TP53 followed by others that are commonly associated with breast cancer. At 17.2 months follow-up, detection of ctDNA was significantly associated with inferior distant disease-free survival (DDFS). Patients with ctDNA had a median DDFS of 32.5 months, while the patients without ctDNA did not reach the median. At 24 months, the DDFS probability was 56% in ctDNA-positive patients versus 81% in ctDNA-negative patients. The multivariate analysis controlled for factors such as residual cancer burden, tumour size, grade, stage, age, and race. Detection of ctDNA remained independently associated with inferior DDFS. It was shown that, overall, ctDNA-positive patients were 3 times as likely to have distant disease recurrence than ctDNA-negative patients. Detection of ctDNA was also associated with inferior overall survival as ctDNA-positive patients had an increased risk of death, 4.1 times higher than ctDNA-negative patients. It was pointed out though, that as the follow-up period is still ongoing, results may change in future analyses.
- Radovich M, et al. GS5-02. SABCS 2019.
« No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide Next Article
Palbociclib not statistically superior to capecitabine in PFS »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.